Literature DB >> 18588334

Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.

Vineet Rakesh1, Andrew D Schweitzer, Oscar Zaragoza, Ruth Bryan, Kevin Wong, Ashim Datta, Arturo Casadevall, Ekaterina Dadachova.   

Abstract

Many microorganisms such as bacteria and fungi possess so-called capsules made of polysaccharides which protect these microorganisms from environmental insults and host immune defenses. The polysaccharide capsule of Cryptococcus neoformans, a human pathogenic yeast, is capable of self-assembly, composed mostly of glucuronoxylomannan (GXM), a polysaccharide with a molecular weight of approximately 2,000,000, and has several layers with different densities. The objective of this study was to model pore-hindered diffusion and binding of the GXM-specific antibody within the C. neoformans capsule. Using the finite-element method (FEM), we created a model which represents the in vivo binding of a GXM-specific antibody to a C. neoformans cell taking into account the intravenous infusion time of antibody, antibody diffusion through capsular pores, and Michaelis-Menten kinetics of antibody binding to capsular GXM. The model predicted rapid diffusion of antibody to all regions of the capsule where the pore size was greater than the Stokes diameter of the antibody. Binding occurred primarily at intermediate regions of the capsule. The GXM concentration in each capsular region was the principal determinant of the steady-state antibody-GXM complex concentration, while the forward binding rate constant influenced the rate of complex formation in each region. The concentration profiles predicted by the model closely matched experimental immunofluorescence data. Inclusion of different antibody isotypes (IgG, IgA, and IgM) into the modeling algorithm resulted in similar complex formation in the outer capsular regions, but different depths of binding at the inner regions. These results have implications for the development of new antibody-based therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588334      PMCID: PMC2680236          DOI: 10.1021/jp8018205

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  25 in total

1.  Transport of protein in the abdominal wall during intraperitoneal therapy. I. Theoretical approach.

Authors:  M F Flessner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-08       Impact factor: 4.052

2.  Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.

Authors:  Michelle E Maxson; Ekaterina Dadachova; Arturo Casadevall; Oscar Zaragoza
Journal:  Eukaryot Cell       Date:  2006-11-17

3.  Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.

Authors:  Oscar Zaragoza; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2006-07-04       Impact factor: 3.715

4.  Antibody diffusion in human cervical mucus.

Authors:  W M Saltzman; M L Radomsky; K J Whaley; R A Cone
Journal:  Biophys J       Date:  1994-02       Impact factor: 4.033

5.  Antigen-antibody binding and mass transport by convection and diffusion to a surface: a two-dimensional computer model of binding and dissociation kinetics.

Authors:  R W Glaser
Journal:  Anal Biochem       Date:  1993-08-15       Impact factor: 3.365

6.  The volume and hydration of the Cryptococcus neoformans polysaccharide capsule.

Authors:  Michelle E Maxson; Emily Cook; Arturo Casadevall; Oscar Zaragoza
Journal:  Fungal Genet Biol       Date:  2006-09-11       Impact factor: 3.495

Review 7.  How does Cryptococcus get its coat?

Authors:  T L Doering
Journal:  Trends Microbiol       Date:  2000-12       Impact factor: 17.079

8.  Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network.

Authors:  R Cherniak; H Valafar; L C Morris; F Valafar
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

Review 9.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Molecular mobility and nucleocytoplasmic flux in hepatoma cells.

Authors:  I Lang; M Scholz; R Peters
Journal:  J Cell Biol       Date:  1986-04       Impact factor: 10.539

View more
  7 in total

1.  Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.

Authors:  Erin E McClelland; André M Nicola; Rafael Prados-Rosales; Arturo Casadevall
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

2.  Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens.

Authors:  R A Bryan; A J Guimaraes; S Hopcraft; Z Jiang; K Bonilla; A Morgenstern; F Bruchertseifer; M Del Poeta; A Torosantucci; A Cassone; J D Nosanchuk; A Casadevall; E Dadachova
Journal:  Mycopathologia       Date:  2011-11-03       Impact factor: 2.574

3.  Effects of radiation type and delivery mode on a radioresistant eukaryote Cryptococcus neoformans.

Authors:  Igor Shuryak; Ruth A Bryan; Jack Broitman; Stephen A Marino; Alfred Morgenstern; Christos Apostolidis; Ekaterina Dadachova
Journal:  Nucl Med Biol       Date:  2015-03-11       Impact factor: 2.408

4.  Predictive models of diffusive nanoparticle transport in 3-dimensional tumor cell spheroids.

Authors:  Yue Gao; Mingguang Li; Bin Chen; Zancong Shen; Peng Guo; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2013-04-20       Impact factor: 4.009

Review 5.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

6.  Species in the Cryptococcus gattii Complex Differ in Capsule and Cell Size following Growth under Capsule-Inducing Conditions.

Authors:  Kenya E Fernandes; Christine Dwyer; Leona T Campbell; Dee A Carter
Journal:  mSphere       Date:  2016-12-28       Impact factor: 4.389

7.  A Predicted Mannoprotein Participates in Cryptococcus gattii Capsular Structure.

Authors:  Julia Catarina Vieira Reuwsaat; Heryk Motta; Ane Wichine Acosta Garcia; Carolina Bettker Vasconcelos; Bárbara Machado Marques; Natália Kronbauer Oliveira; Jéssica Rodrigues; Patrícia Aline Gröhns Ferrareze; Susana Frases; William Lopes; Vanessa Abreu Barcellos; Eamim Daidrê Squizani; Jorge André Horta; Augusto Schrank; Marcio Lourenço Rodrigues; Charley Christian Staats; Marilene Henning Vainstein; Lívia Kmetzsch
Journal:  mSphere       Date:  2018-04-25       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.